Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population

BMC Neurol. 2005 Mar 17;5(1):5. doi: 10.1186/1471-2377-5-5.

Abstract

Background: Simpson-Angus Scale (SAS) is an established instrument for neuroleptic-induced parkinsonism (NIP), but its statistical properties have been studied insufficiently. Some shortcomings concerning its content have been suggested as well. According to a recent report, the widely used SAS mean score cut-off value 0.3 of for NIP detection may be too low. Our aim was to evaluate SAS against DSM-IV diagnostic criteria for NIP and objective motor assessment (actometry).

Methods: Ninety-nine chronic institutionalised schizophrenia patients were evaluated during the same interview by standardised actometric recording and SAS. The diagnosis of NIP was based on DSM-IV criteria. Internal consistency measured by Cronbach's alpha, convergence to actometry and the capacity for NIP case detection were assessed.

Results: Cronbach's alpha for the scale was 0.79. SAS discriminated between DSM-IV NIP and non-NIP patients. The actometric findings did not correlate with SAS. ROC-analysis yielded a good case detection power for SAS mean score. The optimal threshold value of SAS mean score was between 0.65 and 0.95, i.e. clearly higher than previously suggested threshold value.

Conclusion: We conclude that SAS seems a reliable and valid instrument. The previously commonly used cut-off mean score of 0.3 has been too low resulting in low specificity, and we suggest a new cut-off value of 0.65, whereby specificity could be doubled without loosing sensitivity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects
  • Chronic Disease
  • Female
  • Humans
  • Male
  • Mass Screening / instrumentation
  • Mass Screening / standards
  • Middle Aged
  • Neuropsychological Tests / standards*
  • Parkinsonian Disorders / chemically induced*
  • Parkinsonian Disorders / classification*
  • ROC Curve
  • Schizophrenia / drug therapy*
  • Sensitivity and Specificity

Substances

  • Antipsychotic Agents